Close Menu

NEW YORK (360Dx) – Indivumed and Flagship Biosciences today announced a partnership to expand their tissue-based biomarker development capabilities and clinical services to support advanced oncology diagnostics.

Under the terms of the agreement, the companies will offer services that combine Flagship’s experience in biomarker development and Indivumed’s multiplex immunohistochemistry assay development capabilities.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.


This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.